<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA</journal-id><journal-id journal-id-type="iso-abbrev">JAMA</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA</journal-title></journal-title-group><issn pub-type="ppub">0098-7484</issn><issn pub-type="epub">1538-3598</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11320336</article-id><article-id pub-id-type="pmcid-ver">PMC11320336.1</article-id><article-id pub-id-type="pmcaid">11320336</article-id><article-id pub-id-type="pmcaiid">11320336</article-id><article-id pub-id-type="pmid">39133511</article-id><article-id pub-id-type="doi">10.1001/jama.2024.11501</article-id><article-id pub-id-type="publisher-id">joi240081</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="domain" specific-use="print"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="online-first"><subject>Online First</subject></subj-group></article-categories><title-group><article-title>Comparative Safety of In Utero Exposure to Buprenorphine Combined With Naloxone vs Buprenorphine Alone</article-title><alt-title alt-title-type="headline">Safety of In Utero Exposure to Buprenorphine&#8201;+&#8201;Naloxone vs Buprenorphine Alone</alt-title><alt-title alt-title-type="running-head">Safety of In Utero Exposure to Buprenorphine&#8201;+&#8201;Naloxone vs Buprenorphine Alone</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Straub</surname><given-names initials="L">Loreen</given-names></name><degrees>MD</degrees><degrees>MS</degrees><xref rid="joi240081aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bateman</surname><given-names initials="BT">Brian T.</given-names></name><degrees>MD</degrees><degrees>MS</degrees><xref rid="joi240081aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hern&#225;ndez-D&#237;az</surname><given-names initials="S">Sonia</given-names></name><degrees>MD</degrees><degrees>DrPH</degrees><xref rid="joi240081aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhu</surname><given-names initials="Y">Yanmin</given-names></name><degrees>PhD</degrees><degrees>MS</degrees><xref rid="joi240081aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Suarez</surname><given-names initials="EA">Elizabeth A.</given-names></name><degrees>PhD</degrees><degrees>MPH</degrees><xref rid="joi240081aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="joi240081aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vine</surname><given-names initials="SM">Seanna M.</given-names></name><degrees>MPH</degrees><xref rid="joi240081aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jones</surname><given-names initials="HE">Hendr&#233;e E.</given-names></name><degrees>PhD</degrees><xref rid="joi240081aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Connery</surname><given-names initials="HS">Hilary S.</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref rid="joi240081aff7" ref-type="aff">
<sup>7</sup>
</xref><xref rid="joi240081aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Davis</surname><given-names initials="JM">Jonathan M.</given-names></name><degrees>MD</degrees><xref rid="joi240081aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gray</surname><given-names initials="KJ">Kathryn J.</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref rid="joi240081aff10" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lester</surname><given-names initials="B">Barry</given-names></name><degrees>PhD</degrees><xref rid="joi240081aff11" ref-type="aff">
<sup>11</sup>
</xref><xref rid="joi240081aff12" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Terplan</surname><given-names initials="M">Mishka</given-names></name><degrees>MD</degrees><degrees>MPH</degrees><xref rid="joi240081aff13" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zakoul</surname><given-names initials="H">Heidi</given-names></name><degrees>BS</degrees><xref rid="joi240081aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mogun</surname><given-names initials="H">Helen</given-names></name><degrees>MS</degrees><xref rid="joi240081aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huybrechts</surname><given-names initials="KF">Krista F.</given-names></name><degrees>MS</degrees><degrees>PhD</degrees><xref rid="joi240081aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="joi240081aff1"><label>1</label>Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women&#8217;s Hospital and Harvard Medical School, Boston, Massachusetts</aff><aff id="joi240081aff2"><label>2</label>Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, California</aff><aff id="joi240081aff3"><label>3</label>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts</aff><aff id="joi240081aff4"><label>4</label>Center for Pharmacoepidemiology and Treatment Science, Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, New Jersey</aff><aff id="joi240081aff5"><label>5</label>Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, New Jersey</aff><aff id="joi240081aff6"><label>6</label>UNC Horizons and Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill</aff><aff id="joi240081aff7"><label>7</label>Division of Alcohol, Drugs, and Addiction, McLean Hospital, Belmont, Massachusetts</aff><aff id="joi240081aff8"><label>8</label>Department of Psychiatry, Harvard Medical School, Boston, Massachusetts</aff><aff id="joi240081aff9"><label>9</label>Department of Pediatrics, Tufts Medical Center and Tufts Clinical and Translational Science Institute, Boston, Massachusetts</aff><aff id="joi240081aff10"><label>10</label>Department of Obstetrics and Gynecology, University of Washington, Seattle</aff><aff id="joi240081aff11"><label>11</label>Center for the Study of Children at Risk, Departments of Psychiatry and Pediatrics, The Warren Alpert Medical School of Brown University, Providence, Rhode Island</aff><aff id="joi240081aff12"><label>12</label>Women &amp; Infants Hospital, Providence, Rhode Island</aff><aff id="joi240081aff13"><label>13</label>Friends Research Institute, Baltimore, Maryland</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> May 28, 2024.</p><p content-type="published-online"><bold>Published Online:</bold> August 12, 2024. doi:<uri content-type="doi">10.1001/jama.2024.11501</uri></p><corresp id="joi240081cor1"><bold>Corresponding Author:</bold> Loreen Straub, MD, MS, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women&#8217;s Hospital and Harvard Medical School, 1620 Tremont St, Boston, MA 02120 (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="lstraub@bwh.harvard.edu">lstraub@bwh.harvard.edu</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Dr Straub had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><p><italic toggle="yes">Concept and design:</italic> Straub, Bateman, Hern&#225;ndez-D&#237;az, Suarez, Jones, Davis, Lester, Terplan, Huybrechts.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data:</italic> Straub, Bateman, Zhu, Suarez, Vine, Jones, Connery, Davis, Gray, Zakoul, Mogun, Huybrechts.</p><p><italic toggle="yes">Drafting of the manuscript:</italic> Straub, Bateman, Davis, Terplan, Zakoul, Huybrechts.</p><p><italic toggle="yes">Critical review of the manuscript for important intellectual content:</italic> Straub, Bateman, Hern&#225;ndez-D&#237;az, Zhu, Suarez, Vine, Jones, Connery, Davis, Gray, Lester, Terplan, Mogun.</p><p><italic toggle="yes">Statistical analysis:</italic> Straub, Suarez, Vine, Mogun, Huybrechts.</p><p><italic toggle="yes">Obtained funding:</italic> Bateman, Davis, Huybrechts.</p><p><italic toggle="yes">Administrative, technical, or material support:</italic> Bateman, Zhu, Davis, Gray, Lester, Zakoul.</p><p><italic toggle="yes">Supervision:</italic> Bateman, Hern&#225;ndez-D&#237;az, Terplan, Huybrechts.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Straub reported receiving a training grant (T32HD040128) from National Institute of Child Health and Human Development during the conduct of the study. Dr Bateman reported receiving grants from National Institute on Drug Abuse (NIDA) during the conduct of the study. Dr Hern&#225;ndez-D&#237;az reported receiving personal fees from Roche and Moderna and grants from Takeda and UCB outside the submitted work. Dr Zhu reported receiving grants from Takeda outside the submitted work. Dr Davis reported receiving grants from National Institutes of Health (NIH) during the conduct of the study. Dr Gray reported receiving personal fees from BillionToOne, Janssen Global, Aetion, and Roche outside the submitted work. Dr Huybrechts reported receiving grants from NIH/NIDA (R01DA049822) during the conduct of the study and grants to Brigham and Women's Hospital from UCB and Takeda outside the submitted work. No other disclosures were reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> This work was supported by a grant from the National Institute on Drug Abuse (R01DA049822).</p><p><bold>Role of the Funder/Sponsor:</bold> The National Institute on Drug Abuse had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-JOI240081-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2024-08-12T10:00"><day>12</day><month>8</month><year>2024</year></pub-date><pub-date pub-type="ppub"><day>10</day><month>9</month><year>2024</year></pub-date><volume>332</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">468735</issue-id><fpage>805</fpage><lpage>816</lpage><history><date date-type="received"><day>11</day><month>3</month><year>2024</year></date><date date-type="accepted"><day>28</day><month>5</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>02</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>12</day><month>02</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-16 13:25:29.457"><day>16</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright 2024 American Medical Association. All Rights Reserved.</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jama-e2411501.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf-version" xlink:href="jama-e2411501.pdf">jama-e2411501.pdf</self-uri><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.11501"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="companion" xml:lang="en" journal-id="JAMA" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="38294782"><article-title>Buprenorphine Treatment May Be Safer than Methadone During Pregnancy.</article-title><date><day>31</day><month>1</month><year>2024</year></date><source>JAMA</source><pub-id pub-id-type="doi">10.1001/jama.2023.28344</pub-id><pub-id pub-id-type="pmid">38294782</pub-id></related-article><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="companion" xml:lang="en" xlink:title="research-article" journal-id="JAMA" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC11581542"><article-title>Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder</article-title><volume>332</volume><issue>21</issue><date><day>17</day><month>10</month><year>2024</year></date><fpage>1822</fpage><lpage>1831</lpage><source>JAMA</source><pub-id pub-id-type="doi">10.1001/jama.2024.16954</pub-id><pub-id pub-id-type="pmcid">PMC11581542</pub-id><pub-id pub-id-type="pmid">39418046</pub-id></related-article><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-joi240081-1"><title>Question</title><p>Does prenatal exposure to the combination of buprenorphine and naloxone compared with buprenorphine alone increase the risk of adverse neonatal and maternal outcomes?</p></sec><sec id="ab-joi240081-2"><title>Findings</title><p>This observational study noted similar and, in some instances, more favorable neonatal and maternal outcomes for pregnancies exposed to buprenorphine combined with naloxone compared with buprenorphine alone.</p></sec><sec id="ab-joi240081-3"><title>Meaning</title><p>The findings demonstrate comparative safety for the combination of buprenorphine with naloxone for the outcomes considered, supporting both formulations as reasonable options for treating opioid use disorder during pregnancy.</p></sec></abstract><abstract><sec id="ab-joi240081-4"><title>Importance</title><p>Buprenorphine combined with naloxone is commonly used to treat opioid use disorders outside of pregnancy. In pregnancy, buprenorphine alone is generally recommended because of limited perinatal safety data on the combination product.</p></sec><sec id="ab-joi240081-5"><title>Objective</title><p>To compare perinatal outcomes following prenatal exposure to buprenorphine with naloxone vs buprenorphine alone.</p></sec><sec id="ab-joi240081-6"><title>Design, Settings, and Participants</title><p>Population-based cohort study using health care utilization data from Medicaid-insured beneficiaries in the US from 2000 to 2018. The cohort was restricted to pregnant individuals linked to their liveborn infants, with maternal Medicaid enrollment from 3 months before pregnancy to 1 month after delivery and infant enrollment for the first 3 months after birth, unless they died sooner.</p></sec><sec id="ab-joi240081-7"><title>Exposure</title><p>Use of buprenorphine with naloxone vs buprenorphine alone during the first trimester based on outpatient dispensings.</p></sec><sec id="ab-joi240081-8"><title>Main Outcomes and Measures</title><p>Outcomes included major congenital malformations, low birth weight, neonatal abstinence syndrome, neonatal intensive care unit admission, preterm birth, respiratory symptoms, small for gestational age, cesarean delivery, and maternal morbidity. Confounder-adjusted risk ratios were calculated using propensity score overlap weights.</p></sec><sec id="ab-joi240081-9"><title>Results</title><p>This study identified 3369 pregnant individuals exposed to buprenorphine with naloxone during the first trimester (mean [SD] age, 28.8 [4.6] years) and 5326 exposed to buprenorphine alone or who switched from the combination to buprenorphine alone by the end of the first trimester (mean [SD] age, 28.3 [4.5] years). When comparing buprenorphine combined with naloxone with buprenorphine alone, a lower risk for neonatal abstinence syndrome (absolute risk, 37.4% vs 55.8%; weighted relative risk, 0.77 [95% CI, 0.70-0.84]) and a modestly lower risk for neonatal intensive care unit admission (absolute risk, 30.6% vs 34.9%; weighted relative risk, 0.91 [95% CI, 0.85-0.98]) and small for gestational age (absolute risk, 10.0% vs 12.4%; weighted relative risk, 0.86 [95% CI, 0.75-0.98]) was observed. For maternal morbidity, the comparative rates were 2.6% vs 2.9%, respectively, and the weighted relative risk was 0.90 (95% CI, 0.68-1.19). No differences were observed with respect to major congenital malformations overall, low birth weight, preterm birth, respiratory symptoms, or cesarean delivery. Results were consistent across sensitivity analyses.</p></sec><sec id="ab-joi240081-10"><title>Conclusions and Relevance</title><p>There were similar and, in some instances, more favorable neonatal and maternal outcomes for pregnancies exposed to buprenorphine combined with naloxone compared with buprenorphine alone. For the outcomes assessed, compared with buprenorphine alone, buprenorphine with naloxone during pregnancy appears to be a safe treatment option. This supports the view that both formulations are reasonable options for the treatment of opioid use disorder in pregnancy, affirming flexibility in collaborative treatment decision-making.</p></sec></abstract><abstract abstract-type="teaser" specific-use="electronic"><p>This population-based cohort study uses health care utilization data for pregnant individuals with opioid use disorder to compare neonatal and maternal outcomes following prenatal exposure to buprenorphine combined with naloxone vs buprenorphine alone.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>